Three Fool.com contributors believe they've identified truly magnificent growth stocks to buy right now. Here's why they chose AstraZeneca (NASDAQ: AZN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (AstraZeneca): What makes AstraZeneca a magnificent long-term investment is how broad the business is and the potential it has to generate long-term gains.
In a recent forecast, BMO Capital Markets has predicted the global market for innovative weight-loss drugs, such as Novo Nordisk (NYSE:NVO) A/S's Ozempic and Wegovy, to reach $100 billion by 2035. This projection follows an increase in patient recognition of the efficacy of these medications.
Based on analysts' projections, you might think the pharmaceutical giant isn't worth investing in right now.